PureTech's LYT-200 Gains FDA Fast Track for Relapsed MDS Treatment…

Event summary

PureTech's LYT-200 received FDA Fast Track designation for relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS).
End-of-Phase 1 meeting with FDA cleared path for Phase 2 trial (STRIDE-MDS) with 125 patients.
LYT-200 showed 45.5% overall response rate in Phase 1b trial with no dose-limiting toxicities.
PureTech plans to secure external capital in H1 2027 to fund Phase 2 development.

The big picture

PureTech's LYT-200 targets a significant unmet need in HR-MDS, where fewer than 5% of relapsed patients respond to standard retreatment. The FDA Fast Track designation and positive Phase 1b data position LYT-200 as a potential mutation-agnostic therapy in a space dominated by mutation-specific treatments. The upcoming Phase 2 trial will be critical in validating its clinical and commercial potential.

What we're watching

Clinical Validation: Whether STRIDE-MDS confirms LYT-200's Phase 1b efficacy in a randomized setting.
Funding Execution: The pace at which PureTech secures external capital for Phase 2 development.
Regulatory Advantage: How Fast Track designation accelerates LYT-200's path to market.